Trial Profile
Safety and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutetium-177-DOTA-EB-TATE (Primary)
- Indications Neuroendocrine tumours
- Focus First in man; Pharmacokinetics
- 22 Oct 2018 New trial record